News | April 29, 2023
Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
The appointment is effective from May 01, 2023 for five years
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
Subscribe To Our Newsletter & Stay Updated
